The proteome of clear cell ovarian carcinoma

: Ji Jennifer X, Cochrane Dawn R, Negri Gian Luca, Colborne Shane, Miko Sandra E Spencer, Hoang Lynn N, Farnell David, Tessier-Cloutier Basile, Huvila Jutta, Thompson Emily, Leung Samuel, Chiu Derek, Chow Christine, Ta Monica, Köbel Martin, Feil Lucas, Anglesio Michael, Goode Ellen L, Bolton Kelly, Morin Gregg B, Huntsman David G

Publisher: Wiley

: 2022

: Journal of Pathology

: JOURNAL OF PATHOLOGY

: J PATHOL

: 258

: 4

: 325

: 238

: 14

: 0022-3417

: 1096-9896

DOI: https://doi.org/10.1002/path.6006

: https://doi.org/10.1002/path.6006

: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649886/

Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease. (c) 2022 The Pathological Society of Great Britain and Ireland.